These findings, published in the September 2025 issue of the Journal of Surgery, support MPFF as a safe, non-invasive first-line therapy for the management of Hemorrhoidal Disease (HD).
Hemorrhoidal disease (HD) is common and distressing anorectal condition, a frequent cause of patient visits to both primary care and specialist clinics, impacting their comfort, daily activities, and quality of life. The true incidence of HD is challenging to determine, as many affected individuals are reluctant to seek medical care and also hesitant to undergo invasive procedures or surgery. Micronized Purified Flavonoid Fraction (MPFF) offers a pharmacological approach that directly addresses the underlying pathophysiological pathway of HD and or adjunct to invasive interventions as well.
To evaluate the clinical efficacy and patient-reported outcomes of Micronised Purified Flavonoid Fraction (MPFF) in the management of early-grade hemorrhoids, an open-label, prospective, single-center, observational study was conducted, enrolling 12 adults (≥18 years) having Grade I–II hemorrhoids with acute rectal bleeding (<2 days), confirmed on proctoscopy. All participants received MPFF in the form of Daflon 1000 mg tablets. The dosing regimen was in accordance with standard prescribing practices for acute hemorrhoidal episodes: 3 tablets daily for the first four days, followed by 2 tablets daily for the subsequent three days. Based on the patient’s clinical response, treatment could be optionally continued at a dose of one tablet daily until Day 21, with assessments carried out at days 0, 3, 7, 10, 14, and 21 for both physician-reported clinical parameters on proctoscopy and patient reported Quality Of Life (QoL) scores.
The primary outcome was patient-reported QoL measured using HEMO-FISS-QoL score. Secondary outcomes were physician-reported clinical parameters like redness, swelling, bleeding, discharge, tenderness, prolapse, and overall improvement assessed using proctoscopy.
The findings from the study include:
1. Proctoscopic Findings: Over 21-day observation, a marked reduction in redness and swelling was noted. By day 14, about 50% of patients were free from redness, 25% from swelling. By the end of day 21, 91% (almost all patients) had no visible redness or swelling.
(Graph 1)
Graph 1: Proctoscopic Examination: Change in Redness and Swelling till the End of the Study
2. Quality of life (QOL) Assessment (HEMO-FISS-QoL score): By Day 21, patients showed substantial improvements across all domains. Overall QoL score decreased from 45.51 ± 8.01 at baseline to 2.80 ± 1.84 at Day 21 (mean change −42.70 ± 7.57; p < 0.05), suggesting significant improvement in QoL.
Conclusion: MPFF administration was associated with a progressive reduction in proctoscopic inflammation and significant improvements in QoL. These findings suggest that MPFF may be a valuable adjunct in conservative management of HD, offering both objective mucosal healing and subjective symptomatic benefits in patients with Grade I-II hemorrhoids
Reference: Porwal A (2025) Integrating Proctoscopic Assessment With Patient Experience of Micronized Purified Flavonoid Fraction in Treatment of Grade I–II Hemorrhoids: the IMPACT-HD. J Surg 10: 11435 https://doi.org/10.29011/2575-9760.011435
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.